Loading
Bladder and Urothelial Cancer Treatments / Endometrial and Cervical Cancer Treatments · Journal article
Human Vaccines & Immunotherapeutics · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single-patient case report documenting severe sintilimab-related cystitis/ureteritis in a 44-year-old woman with high-grade endometrial stromal sarcoma, with response to corticosteroids and subsequent tolerance upon rechallenge. The report identifies a rare immune-related adverse event and provides clinical management observations, but does not quantify incidence, risk factors, or comparative outcomes.
Single case report with structured literature review. One 44-year-old female patient with high-grade endometrial stromal sarcoma receiving immune checkpoint inhibitor therapy. Intervention: Sintilimab combined with nab-paclitaxel and carboplatin for 3 cycles; subsequent treatment with methylprednisolone and piperacillin-tazobactam; rechallenge with sintilimab; later switch to tislelizumab.
44-year-old female with high-grade endometrial stromal sarcoma developed severe urinary frequency, urgency, and dysuria after 3 cycles of sintilimab combined with nab-paclitaxel and carboplatin Imaging showed diffuse thickening of bladder and ureteral walls with marked peri-vesical and peri-ureteral exudation Symptoms improved dramatically after methylprednisolone treatment
Single case; no incidence data or risk factors for this adverse event reported
Clinicians should maintain awareness of immune checkpoint inhibitor-related cystitis/ureteritis as a rare but serious urological adverse event and consider corticosteroid treatment for symptomatic relief. Rechallenge with the same ICI or switch to an alternative checkpoint inhibitor may be feasible depending on severity.
A single case report with literature review describing a rare adverse event; provides clinical observation and management guidance but lacks comparative data or controlled evidence of incidence or causality.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should maintain awareness of immune checkpoint inhibitor-related cystitis/ureteritis as a rare but serious urological adverse event and consider corticosteroid treatment for symptomatic relief. Rechallenge with the same ICI or switch to an alternative checkpoint inhibitor may be feasible depending on severity.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Immune checkpoint inhibitors (ICIs) are cutting‑edge therapies in cancer treatment; however, they may trigger unique immune‑related adverse events (irAEs). Although irAEs can affect various organs, ICI‑induced cystitis/ureteritis has rarely been reported. We present a 44‑year‑old female patient with high‑grade endometrial stromal sarcoma who developed severe urinary frequency, urgency, and dysuria after three cycles of sintilimab combined with nab‑paclitaxel and carboplatin. Empirical antibiotic therapy failed to relieve her symptoms. Imaging revealed diffuse thickening of the bladder and ureteral walls with marked peri‑vesical and peri‑ureteral exudation. After treatment with methylprednisolone, the patient's symptoms improved dramatically. A subsequent urine culture grew Enterococcus faecalis, and the addition of piperacillin-tazobactam resulted in further symptom resolution. Following symptom resolution, she was rechallenged with sintilimab and developed only mild urinary tract symptoms. Subsequently, due to disease progression, treatment was switched to tislelizumab, and the urinary symptoms did not recur. The patient's urinary symptoms were sintilimab‑related cystitis/ureteritis with possible concomitant or partially suppressed bacterial infection. This case, together with a structured literature review of other immunotherapy‑related cystitis/ureteritis cases and subsequent ICI use, provides a practical reference for the diagnosis and management of ICI‑related urological irAEs and for subsequent anti‑tumor treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.